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AbstrAct
background Critical limb ischaemia (CLI) is 
a severe manifestation of peripheral arterial 
disease, characterised by chronic ischaemic 
rest pain, ulcers or gangrene. Management of 
ischaemic pain is challenging in patients with 
no options for revascularisation and optimal 
pharmacological therapies have not been 
established.
Objectives To identify and evaluate the 
effectiveness of pharmacological therapies 
to treat ischaemic pain secondary to non-
reconstructable CLI.
Methods This systematic review was reported 
in accordance with PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-
Analyses) guideline. Comprehensive searches of 
three electronic databases, a PubMed-related 
articles link search, grey literature search and 
hand-searches of the bibliographies of relevant 
papers and textbooks were performed. Studies 
recruiting adult patients with CLI of any 
aetiology were eligible for inclusion. Surgical 
and revascularisation procedures, and all invasive 
interventions were excluded.
results Of 792 studies, six met full inclusion 
criteria. These studies researched the use of 
intravenous lidocaine, intravenous ketamine, oral 
gabapentin and the combination of transdermal 
buprenorphine and epidural morphine/
ropivacaine infusion. All studies showed an 
improvement in severity of ischaemic pain in 
CLI but with varying side effect profiles and 
quality. The extracted studies showed substantial 
heterogeneity and therefore a meta-analysis was 
not performed.
conclusion The pharmacological management 
of pain secondary to non-reconstructable CLI is 
a challenging review topic. No recommendations 
of pharmacological agents can be made 
following this review but a number of novel 
approaches to manage pain in this cohort 
have shown positive results and require further 
investigation.
bAckgrOund
definition
The Inter-Society Consensus for the 
Management of Peripheral Arterial 
Disease (TASC II) defines critical limb 
ischaemia (CLI) as the following: any 
patient with chronic ischaemic rest pain, 
ulcers or gangrene attributable to objec-
tively proven arterial occlusive disease.1 
CLI is a chronic condition, distinct from 
acute limb ischaemia.
CLI is a severe stage of peripheral arte-
rial disease. Patients with CLI can be 
classified in the grades of the Fontaine 
classification (stages III–IV) or the Ruth-
erford classification (grades 4–6). Not all 
patients progress through the predefined 
stages from claudication to CLI.2 Progres-
sion to CLI is often variable and unpre-
dictable.
Epidemiology
CLI will develop in 500–1000 patients 
annually in a Western population 
of 1 million people.1 It is associ-
ated with surgery, hospitalisation and 
death.3 Patients with CLI have cardio-
vascular event rates higher than those 
in patients with symptomatic coronary 
artery disease.4 Thomas et al found that 
in patients with conservatively treated 
severe CLI, all-cause mortality was 58% 
with a 2-year survivability rate of 55%.5 
The 5-year mortality exceeds that of 
colorectal cancer, breast cancer, stroke, 
acute myocardial infarction and prostate 
cancer.6
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Pathophysiology of cLI and ischaemic pain
Most commonly, CLI is caused by atherosclerosis. 
Other causes include vasculitis, thromboembolic 
disease, arterial embolic disease, in situ thrombosis, 
cystic adventitial disease, thromboangiitis obliterans 
or trauma. Irrespective of the underlying cause, the 
pathophysiology of CLI is complex. There are three 
main mechanisms underlying the pathophysiology: 
haemodynamic abnormalities, oxidative stress and 
alterations in skeletal muscle metabolism. All compen-
satory mechanisms to retain skin perfusion become 
ineffective.
Chronic ischaemic pain has a significant neuropathic 
component. This is proposed to be secondary to a 
distal axonopathy affecting nerve fibres of all sizes. 
Blood flow in the lower limbs of patients with CLI 
correlates with neurological symptom scores and elec-
trophysiological testing.7
Ischaemic pain and impact on quality of life
CLI is primarily characterised by pedal rest pain. It is 
typically worse at night (when the limb is no longer 
in a dependent position), often waking patients from 
their sleep. Pain from ulceration also occurs. Multiple 
studies have shown that chronic ischaemic pain nega-
tively impacts on multiple dimensions of quality of 
life.8–10
treatment of cLI
The therapeutic goals in treating CLI include increasing 
survival, relieving ischaemic pain, healing areas of 
ulceration, preventing major amputations, improving 
function and improving quality of life. TASC II recom-
mends that for all patients with CLI, an early referral 
should be sent to a vascular specialist to plan for 
revascularisation.1 Simultaneously, a multidisciplinary 
approach to control pain, risk factors and comorbidi-
ties is recommended.1 Throughout the disease trajec-
tory, pain control is important to improve quality of 
life, and to reduce the risk of phantom limb pain in 
patients who go on to require amputation.11
When open or endovascular intervention has failed, 
or is not possible, pharmacotherapy for CLI is the next 
step to consider. A 2010 Cochrane review concluded 
that there is no conclusive evidence for the long-term 
effectiveness and safety of prostanoids in patients with 
CLI, despite some positive results regarding rest-pain 
alleviation, healing of ulcers and amputations.12 With 
regard to vasoactive drugs, a Cochrane review found 
that intravenous naftidrofuryl for CLI was ineffective 
in reducing the symptoms of CLI.13
Palliation and cLI
TASC II reports that ultimately, the majority of care of 
patients with CLI is palliative in nature.1 In an ageing 
comorbid population, preferred revascularisation or 
surgery is often not an option. There are little data 
on the outcome of conservative therapy. Most research 
focuses on physician-reported outcome measures 
(graft patency, survival, and so on). Research studies 
including patient-reported outcome measures are 
limited. Recognising patients in need of palliative care, 
recording discussions about their management and a 
high standard of end of life care are all vital.14
Ideally, pain control is achieved by reperfusion of the 
ischaemic limb. When this is not possible or fails due to 
either the patient or disease status, pain management 
is challenging. Interventional pain procedures, such 
as spinal cord stimulation (SCS) and lumbar sympa-
thectomy, may have a role in achieving pain control 
but evidence to date is inconclusive. Pain manage-
ment is therefore challenging for multiple reasons: 
complex pathophysiology resulting in predominantly 
neuropathic pain, poor tolerance of strong opioids in 
a cohort with multiple comorbidities often including 
chronic kidney disease, regional anaesthesia inconsis-
tently effective for ischaemic pain and a limited pool 
of research specifically targeting ischaemic pain.15
Patients with CLI have severe pain, poor quality of 
life and limited prognosis. If these patients are ulti-
mately being treated in a palliative approach, what 
evidence do we have for the effectiveness of inter-
ventions to treat pain when all other options for limb 
salvage (revascularisation, surgery, pharmacotherapies) 
are exhausted? This systematic review was conducted 
to identify and evaluate the most effective therapies 
available to treat ischaemic pain in patients with CLI 
without options for limb salvage.
Objective
To identify and evaluate the effectiveness of pharma-
cological therapies to treat ischaemic pain secondary 
to non-reconstructable CLI.
Methods
This systematic review was reported in accordance 
with the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guideline.16
IdEntIfIcAtIOns Of studIEs (IncLusIOn/
ExcLusIOn crItErIA)
types of studies
All study designs were eligible for inclusion apart from 
single case reports. Single case reports were reviewed 
but excluded from the data extraction process. Studies 
that met the inclusion criteria were randomised 
controlled trials (RCTs), quasiexperimental studies, 
observational studies with/without control groups and 
case series.
types of participants
Studies recruiting adult patients with CLI (as defined 
by TASC II1) were eligible for inclusion. Any under-
lying cause of CLI was included. Healthy volunteers 
with experimentally induced ischaemic pain were 
excluded.
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types of interventions
Any pharmacological interventions to treat ischaemic 
pain were included. Surgical and revascularisation 
procedures were excluded. All invasive interventions 
were excluded, such as SCS and lumbar sympathec-
tomy. Detailed explanation of the roles of these inter-
ventions and reasons for exclusion are outlined below.
Spinal cord stimulation
In SCS, a device which stimulates sensory fibres 
through electrodes is implanted in the epidural space. 
RCTs conducted to evaluate SCS have limb salvage 
as their primary outcome with pain relief included in 
the secondary outcomes. The most recent Cochrane 
Review (2013) analysed evidence from six RCTs 
and reported that there was some evidence SCS 
had a beneficial effect on pain relief in comparison 
to optimum conservative treatment.17 A systematic 
review conducted in 2009 which specifically looked 
at the role of SCS for pain management reported that 
trial evidence failed to demonstrate that pain relief in 
CLI was better for SCS than for conventional medical 
management.18 No newer trials were included in the 
2013 Cochrane Review. In addition, SCS is a costly 
and invasive procedure.
Lumbar sympathectomy
The specific role of lumbar sympathectomy in CLI is 
still unclear. A protocol for a Cochrane review of the 
role of lumbar sympathectomy in CLI was published 
last year, therefore further insight into the role of this 
procedure in CLI will follow.19 The studies likely to be 
included did not however meet inclusion criteria for 
this review (non-pharmacological therapy, invasive, 
primary outcomes relating mostly to limb salvage).
types of outcome measures
The primary outcome measure was reduction in pain 
score, as measured by a visual analogue scale (VAS), 
Brief Pain Inventory20 or other scoring methods. 
Secondary outcome measures included opioid require-
ments, findings of allodynia, hyperpathia, or hyper-
algesia on examination, hours of sleep, and depres-
sion and anxiety scores. Side effect profiles of each 
intervention were included in the data analysis. Only 
studies with the primary outcome measure related 
to ischaemic pain relief in CLI were included in the 
data analysis. This excluded studies with the primary 
outcome measures relating to limb salvage and 
secondary outcomes relating to pain management.
search methods
Searching of three electronic databases was conducted 
(access via Ovid): MEDLINE (Ovid MEDLINE(R) 
In-Process and Other Non-Indexed Citations and Ovid 
MEDLINE(R) 1946 to December 2016), EMBASE 
(1974 to December 2016), Cochrane Library.
For each database, a detailed search strategy was 
developed (eg, online supplementary appendix 1).
Related article search
A PubMed ‘related articles’ link search was conducted 
which has been shown to be useful for reviewing 
complex evidence.21
Language
Only studies published in the English language were 
eligible for the systematic review.
Date range
Only studies published between 1996 and December 
2016 were included (20-year span).
Book search
Two palliative care textbooks were reviewed to iden-
tify articles relating to CLI pain management: Oxford 
Handbook of Palliative Care and Palliative Medi-
cine.22 23
Grey literature
To identify relevant unpublished written material or 
published abstracts or conference proceedings Open-
Grey (www. opengrey. ey/) was searched.
data collection and analysis
Selection of studies
Once the search strategy was completed, a list of titles 
of studies was reviewed to decide whether they met 
inclusion criteria. The abstract was read if it was unclear 
whether the study should be included. If there was still 
doubt the full paper was reviewed. Following this, a 
final list of included studies was generated and data 
were extracted.
Data extraction and management
Predesigned data extraction forms were filled by one 
reviewer during the data extraction process. To manage 
citations and tracking of studies throughout the stages 
of this review, RefWorks software was used.24
The following data were extracted: publication 
details, country origin, study design, study setting, 
recruitment period, follow-up duration, type of data 
collected, sample size, gender, age, primary outcome 
measure, secondary outcome measure(s), intervention 
details, adverse effects, evidence level.
Assessment of quality of studies
The risk of bias of each study was assessed using the 
Cochrane Risk of Bias tool for RCTs and the ROBINS-I 
tool for non-randomised trials.25 26 The evidence 
was then graded using SIGN Levels of Evidence and 
Grading Recommendations.27
Data synthesis
Due to heterogeneity among the included studies, 
meta-analysis could not be performed.
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rEsuLts
description of studies
Characteristics of included studies are outlined in 
table 1.
search results
Following the initial database search, 1086 studies 
were listed. Following automatic removal of duplicates 
by RefWorks, 792 were identified. After reviewing the 
titles and/or abstracts of 792 studies, nine articles were 
reviewed and assessed for eligibility. Six were found to 
be suitable for inclusion in the analysis (online supple-
mentary appendix 2, PRISMA flow diagram).
Included studies
Six studies met inclusion criteria. This included five 
RCTs as follows: double-blind parallel conventional 
therapy controlled, double-blind parallel placebo 
controlled, double-blind crossover, single blind 
parallel open label, prospective randomised trial. The 
one remaining study was a prospective observational 
pilot study.
Interventions used
The following interventions were used in the studies 
included: intravenous lidocaine, oral gabapentin, 
intravenous ketamine and transdermal buprenorphine 
on patients already commenced on epidural morphine/
ropivacaine. Studies investigating prostanoids were 
excluded as the primary outcome measure did not 
relate to ischaemic pain relief.
Participants
Sample sizes ranged from 8 to 86. Two hundred and 
thirty-two patients were recruited over the six included 
studies. All patients had ischaemic pain secondary to 
CLI and were under the care of a vascular surgery 
service. One study included participants with CLI still 
awaiting surgery28 : this study was deemed appro-
priate to include as the underlying nature of the pain 
was no different from patients with CLI not suitable 
for surgery (in both cases the pain experienced was 
ischaemic pain secondary to CLI). The other reason 
to include this study is that the majority of patients 
in practice suffering from pain secondary to CLI are 
often left on surgical waiting lists in an attempt for 
revascularisation, however, never get to surgery due to 
their deteriorating state.
settings
Included studies were conducted in UK, Italy, Sweden 
and Iran. Most participants were outpatients. One 
study recruited inpatients awaiting surgery.
Excluded studies
List of excluded studies and reasons for exclusion are 
outlined in table 2.29–31
Quality of included studies
The quality assessments of included studies are 
outlined in tables 3–5.
The double-blind parallel RCT by Vahidi et al scores 
1++ as it appeared to have very low risk of bias 
(SIGN grading system27). It, however, had a very short 
follow-up time of 30 min. Persson et al’s ketamine 
RCT contained only eight patients with no sample size 
calculation, therefore it is likely underpowered and at 
risk of being influenced by random fluctuations which 
may overestimate any effects. This was accounted for 
under the ‘other bias’ category of the Cochrane tool 
(Cochrane Risk of Bias Assessment25). This study also 
had a limited follow-up time of 60 min. Mitchell and 
Fallon's RCT on ketamine was a well-designed double-
blind placebo controlled RCT; however, seven with-
drew during the study and this resulted in attrition 
bias. Both trials by Aurilio et al were at high risk of 
bias. They were open-label trials, at risk of both perfor-
mance and detection bias. The 2005 trial by Aurilio et 
al also did not outline the random sequence genera-
tion process or allocation concealment process. The 
2010 study by Morris-Stiff et al on gabapentin was 
a prospective observational study without a control 
group. This study was deemed to have a serious risk 
of selection bias (ROBINS-I tool26). It was graded 3, 
as per SIGN grading system, reflecting its poor-quality 
design and high risk of bias.
EffEcts Of IntErvEntIOns
Results of included studies are outlined in table 6.
Lidocaine
Vahidi and colleagues compared intravenous lidocaine 
to intravenous morphine in patients with CLI.32 Prior 
to the infusion, the mean VAS score in the lidocaine 
group was 7.50 and in the morphine group was 7.65. 
After 15 min, the mean VAS score in the group that 
received lidocaine was lower than in the morphine 
group (5.75±1.77 vs 7.00±1.83; mean difference 
1.25, 95% CI 0.095 to 2.405). At 30 min, the mean 
VAS score lowered further in the lidocaine group in 
comparison to the morphine group (4.25±1.48 vs 
6.50±1.73; mean difference 2.25, 95% CI 1.218 to 
3.282).
ketamine
Mitchell and Fallon compared ketamine 0.6 mg/kg 
in 0.9% saline over 4 hours with normal saline over 
4 hours on a background of the patient’s regular 
opioid usage.33 In the ketamine group, percentage 
pain relief attributed to medication improved from 
50% preinfusion to 65% 24 hours postinfusion and 
69% 5 days postinfusion. In the placebo group, 
percentage pain relief attributed to medication went 
from 58% preinfusion to 56% 24 hours postinfusion 
and 50% 5 days postinfusion (p<0.05 using the t-test 
and the Wilcoxon rank-sum test). The intervention 
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group also showed an improvement in effect of pain 
on general activity (p<0.03) and on enjoyment of life 
(p<0.004). No statistically signiﬁcant difference was 
seen in opioid requirements between the ketamine and 
placebo groups.
In the Persson et al ketamine trial, racemic ketamine 
hydrochloride was administered intravenously over 5 
min at doses of 0.15, 0.3 and 0.45 mg/kg on respective 
study days.34 This was compared with morphine 10 mg 
intravenously over the same time interval. Ketamine 
0.30 mg/kg provided total pain relief in seven of eight 
patients, whereas ketamine 0.45 mg/kg provided total 
pain relief in all eight patients. Pain relief lasted up to 
10 min and then decreased steadily to a median value 
to 50% at 60 min. However, there was no statistically 
significant difference between the analgesic effect of 
ketamine 0.45 mg/kg and morphine 10 mg at peak 
effect times (5 and 20 min, respectively) (p<0.10, 
Wilcoxon test).
gabapentin
In Morris-Stiff et al’s paper, the median pain score 
was 9 at presentation and significantly reduced 
compared with baseline each of the assessment days 
(day 4: 7 (p=0.001), day 7: 7 (p=0.0002), day 14: 
6 (p=0.0004), day 28: 5 (p=0.0003)).35 Two of the 
17 patients failed to show an improvement in pain 
scores. Fifteen patients reported an improvement in 
night pain, with secondary better sleep and perceived 
improvement in quality of life. The median dose was 
1271 mg; four were adequately pain controlled on 
300 mg three times a day, nine on 1200 mg, and the 
remainder on 600 mg three times a day. There was no 
control group to compare effect.
transdermal buprenorphine + epidural morphine/
ropivacaine
In Aurilio et al’s 2009 trial, there was a signiﬁcant 
difference (p<0.0001) at the end point between the 
intervention group, with a mean VAS score of 10 mm (a 
reduction of 88%), and the control group, with a mean 
VAS score of 19 mm (a reduction of 77%).36 Patients 
receiving a 35 mg/hour buprenorphine patch demon-
strated signiﬁcantly lower Short-Form McGill Pain 
Questionnaire scores, mean total score and present 
pain intensity compared with those receiving the 
placebo patch (p<0.0001). At the end point, the 
mean score for sleep quality was signiﬁcantly better 
in the intervention group (p<0.0001). The number of 
patients requiring rescue morphine was lower in inter-
vention group during each week. There were no signif-
icant differences in the neurobehavioural status of the 
patients (p<0.165). In the 2005 trial, mean VAS at 
baseline was 85 in both groups.28 At day 15 it reduced 
to 20 in the intervention and 38 in the control, and 
Table 2 Excluded studies
Reference Intervention Reason for exclusion
Tawfic et al29 Ketamine Case report
Heartsill 
and Brown30
Gabapentin Case report
Fletcher et al31 Locally applied 
transdermal nitrate 
patches
Patients had ‘distal limb 
ischaemia’ but the paper 
did not provide sufficient 
information to confirm that 
patients had  critical limb 
ischaemia
Table 3 Cochrane tool to assess risk of bias for randomised controlled trials
Vahidi et al32 Aurilio et al36 Aurilio et al28 Mitchell and Fallon33 Persson et al34
Random sequence generation (selection bias) + + ? + +
Allocation concealment (selection bias) + + ? + +
Blinding (performance bias and detection bias)
All outcomes
+ − − + +
Incomplete outcome data (attrition bias)
All outcomes
+ + + − +
Selective reporting (reporting bias) + + + + +
Other bias + + + + −
Table 4 Risk of bias in non-randomised studies (ROBINS-I tool)
Morris-Stiff  
et al35
Bias due to confounding +
Bias in selection of participants into the study  −
Bias in classification of interventions +
Bias due to deviations from intended interventions +
Bias due to missing data +
Bias in measurement of outcomes +
Bias in selection of the reported result +
Overall bias Serious risk
Table 5 Quality assessment according to SIGN grading system
Study 1++ 1+ 1− 2++ 2+ 2− 3 4
Vahidi et al32 x
Morris-Stiff et al35 x
Aurilio et al36 x
Aurilio et al28 x
Mitchell and Fallon33 x
Persson et al34 x
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at day 30 it reduced further to 10 in the intervention 
and 20 in the control. In the intervention, group mean 
hours of sleep improved from 3.5 to 5 to 8 and in 
the control from 3.5 to 4.5 to 6. No patients in the 
intervention group required additional morphine, in 
comparison to 11 in the control. No statistical analysis 
was performed on these results.
Adverse effects
All trials involved close monitoring for adverse 
effects. No side effects were reported in the intra-
venous lidocaine trial. In the lidocaine group, there 
were no reported adverse effects such as nausea, 
lightheadedness or perioral numbness. Following 
close monitoring, no serious complications (respi-
ratory arrest, hypotension or cardiac arrhythmia) 
were observed. ECG readings were unchanged post-
infusion. However, patients were only followed 
up for 30 min postinfusion. In Morris-Stiff et al’s 
trial, patients were followed for 28 days following 
commencement of gabapentin to monitor for side 
effects. There were no documented side effects. Both 
ketamine trials reported significant adverse effects 
in the intervention groups. In Mitchell and Fallon’s 
trial, despite all patients receiving oral haloperidol 
1.5 mg on the evening of the infusion, 33% of patients 
reported feeling ‘more emotional than usual’ 24 hours 
after the ketamine; 6% of the placebo group reported 
this symptom (OR of 7.7; p=0.05). In Persson et 
al’s trial, side effects were divided into two groups: 
circulation and psychotropic. There was a marginal 
effect on systolic blood pressure after varying doses 
of ketamine (mean blood pressure rises approxi-
mately 10% for ketamine dose (0.45 mg/kg)). There 
was no significant effect on heart rate. All patients 
in the ketamine group experienced perceptual distur-
bances and psychotropic effects. These effects were 
dose dependent; at the highest dose all patients had 
side effects deemed ‘unacceptable’ even for a short-
term treatment. Unacceptable side effects were effects 
which involved disturbances of perception, dizziness/
vertigo or pronounced sedation. No patients received 
antipsychotic therapy to limit adverse effects. No 
patients withdrew because of adverse effects. Both 
Aurilio et al’s trials on the combination of buprenor-
phine and epidural morphine/ropivacaine found 
higher incidences of adverse effects in the control 
group (2009 trial: 59% vs 81%, p<0.001; 2005 trial: 
45% vs 71%, no p value reported). All side effects 
reported were common opioid-induced effects 
(drowsiness, fatigue, constipation and nausea). With-
drawal from the trials occurred in one patient from 
the control group in the 2005 trial and two patients 
from the control group in the 2009 trial. The higher 
rate of symptoms reported in the control group 
was felt to be secondary to the increased need for 
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additional rescue doses of epidural morphine in the 
control group.
dIscussIOn
Despite TASC II stating that the management of CLI 
is ultimately palliative in nature, there is a surpris-
ingly limited research base for the use of analgesics 
to manage ischaemic pain in CLI. This systematic 
review only identified six studies conducted in CLI 
with a primary outcome measure assessing ischaemic 
pain management. The majority of studies focused on 
limb salvage or include invasive or surgical interven-
tions. In practice, however, the majority of patients 
referred to palliative or pain management services may 
be approaching end of life due to non-reconstructable 
CLI and pain management is challenging. This system-
atic review has identified a small number of studies but 
with some promising approaches to manage pain in 
this frail, elderly, comorbid population.
Two RCTs comparing ketamine with normal saline 
and morphine sulfate showed significantly reduced 
pain scores in the intervention groups. Ketamine was 
found to improve ischaemic pain when compared with 
normal saline, but when compared with morphine at 
equivalent peak dose time intervals there was no statis-
tical difference. Both studies had high rates of adverse 
effects. In the Persson et al's study, all patients receiving 
the higher dose of ketamine had ‘unacceptable’ side 
effects. Mitchell and Fallon pre-empted the known 
side effects of ketamine by using haloperidol to limit 
the severity of these symptoms. Despite this, however, 
in the ketamine group significantly more patients 
reported feeling more emotional than usual after the 
infusion. Ketamine is a controversial drug in palliative 
care. Multiple papers have researched its effective-
ness in varying pain syndromes, predominantly with 
neuropathic components.37 38 However, the side effect 
profile continues to be the limiting factor in its use. 
The overall benefit of ketamine to treat pain secondary 
to CLI is, therefore, still questionable.
Vahidi et al’s trial researching the use of intrave-
nous lidocaine is the first conducted in patients with 
CLI. Previous research by Frölich et al showed that 
lidocaine had an inhibitory effect on ischaemic pain, 
producing a sustained analgesic state in ischaemic pain 
induced by the tourniquet technique in healthy indi-
viduals.39 This is a promising new analgesic approach. 
This RCT also identified no adverse effects, which 
is favourable in a frail population with limited prog-
nosis, in which improved quality of life should be the 
focus of all clinicians treating these patients. However, 
adverse effects were not monitored for longer than 
30 min postinfusion, therefore caution is needed prior 
to use. The role of lidocaine for more sustained pain 
relief is also unknown at present.
Two studies conducted by Aurilio et al discussed the 
benefit of a partial opioid antagonist (buprenorphine) 
in addition to an epidural infusion of morphine and 
ropivacaine. The additional benefit of buprenorphine 
is felt to be secondary to the following mechanisms: 
reduced central hypersensitisation typical of the 
various forms of chronic pain, different site of action 
to morphine possibly resulting in a synergic effect by 
associating the two drugs and possible reduction in 
the incidence of the side effects.36 Certainly, in both 
Aurilio and colleagues’ RCTs the intervention group 
had lower side effect profiles than the control which 
required higher doses of morphine.
Gabapentin is licensed for the treatment of periph-
eral and central neuropathic pain in adults at doses 
up to 3.6 g daily. It is thought to act by binding to 
calcium channels, modulating calcium influx which 
results in analgesic, antiepileptic and sedative effects. 
Gabapentin is a widely used neuropathic agent in both 
the palliative and pain medicine services. In a prospec-
tive observational study of patients with non-recon-
structable CLI, gabapentin significantly reduced pain 
scores, improved sleep, and in some, reduced opioid 
requirements with no documented side effects. Due to 
the limitations of the study design and lack of control 
group, recommendations cannot be made with regard 
to the use of gabapentin for this cohort of patients on 
this level of evidence.
LIMItAtIOns
This review has a number of limitations. First, the elec-
tronic database searching was limited to three data-
bases: Medline, Embase and the Cochrane Library. 
Further papers may have been identified if a more 
extensive search strategy was conducted; for example, 
including databases such as Web of Science and Scopus 
or conducting a broader search of the grey literature. 
This review also only included studies published in the 
English language and within the last 20 years, therefore 
limiting the scope of papers to analyse and interpret. 
The search was limited to studies published in the last 
20 years due to the fact that the scoping searches 
showed little earlier evidence. Of those limited number 
of studies that were available prior to 1996, all were of 
poor-quality design. Studies were limited to the English 
language as language resources were not available to 
perform more in-depth searching. A further weakness 
of this review is that only one reviewer developed the 
search terms (which were not validated but developed 
with a librarian), selected studies for inclusion and 
conducted the data extraction process. At least two 
reviewers are recommended to complete this process. 
This review also restricted itself only to the pharma-
cological therapies available for management of isch-
aemic pain in CLI. SCS and lumbar sympathectomy 
may have a role in a specific subset of patients with 
non-reconstructable CLI. However, studies relating to 
these procedures were excluded from this review. For 
this review, there were no specifications with regard 
to adequate follow-up periods. Ideally, a follow-up 
of at least 1 week would be advisable; however, this 
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was not possible due to lack of evidence. Particular 
attention needs to be made to the fact that there were 
two studies included in this review with very short 
follow-up periods: Vahidi et al (30 min) and Persson 
et al (60 min).
cOncLusIOn
The pharmacological management of pain secondary 
to non-reconstructable CLI is a challenging review 
topic. This is due to the complex pathophysiology of 
pain in CLI, limited research base, differing pharma-
cological interventions and varying quality of relevant 
studies. Synthesis of the included studies to help guide 
our clinical management of ischaemic pain in non-re-
constructable CLI is difficult. Optimising neuropathic 
pain control appears to be a cornerstone of manage-
ment. No recommendations of pharmacological agents 
can be made following this review, but a number of 
novel approaches to manage pain in this cohort have 
shown positive results and require further investiga-
tion. These include the use of intravenous lidocaine 
for short-term relief of ischaemic pain in non-recon-
structable CLI and the addition of buprenorphine in 
patients already receiving epidural morphine and local 
anaesthetic. Gabapentin cannot be recommended on 
the basis of one positive observational uncontrolled 
study. The debate surrounding the benefit of ketamine 
in varying pain states still exists, with our review 
not supporting its use in CLI on the current level of 
evidence.
Implications for research
There are a number of research possibilities emerging 
following this review. Intravenous lidocaine use for 
ischaemic pain looks promising; however, further 
research needs to assess its use and safety over a 
longer duration. With regard to ketamine, further 
research would be beneficial into alternative dosing 
regimens and routes of administration (oral, subcuta-
neous or intravenous) to assess better tolerability and 
further assess effectiveness. These trials should use 
conventional therapy as a control, such as morphine 
sulfate. They should also include prophylactic anti-
psychotic medication to limit side effects. The use 
of gabapentin has only been assessed in a prospec-
tive observational study; a double-blind controlled 
RCT compared with conventional therapy should be 
conducted. The role of other neuropathic agents such 
as pregabalin, duloxetine and amitriptyline needs to 
be researched.
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